On February 17, 2022, Nalu Medical, Inc., a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced a $104 million equity financing. The round was led by new investors MVM Partners and Gilde Healthcare. New investors Pura Vida Investments and Aperture Venture Partners, as well as existing investors Advent Life Sciences, Decheng Capital, Endeavour Vision, and Longitude Capital, also participated in the round. The proceeds from this financing are intended to be used for scaling commercial operations to accelerate growth, continued expansion of clinical evidence, and continuing product development, in addition to other general corporate purposes. Wilson Sonsini Goodrich & Rosati advised Nalu Medical on the transaction.

The Wilson Sonsini team that advised Nalu Medical on the transaction included Marty Waters, Scott Murano, Zach Myers, Eric Hsu, Daniel Cho, Daniel Canavan, Won Chong, and Sam Silverstein.

For more information, please see Nalu Medical's press release.